DIETARY SUPPLEMENTS
Découvrez 08 - Slim
Your ally for a slimmer figure and healthy weight
Journal
Parkinson’s disease is still widely defined by its most visible symptoms: tremors, stiffness, and slowed movement. But this definition reflects a late stage of the disease, not its beginning.
What is now becoming clear in the scientific literature is far more unsettling—and far more actionable.
Parkinson’s disease often begins years, sometimes decades, before any motor symptoms appear. And in many cases, the earliest warning signs do not seem neurological at all. They emerge quietly, through the gut, energy metabolism, and subtle changes in sensory and sleep functions [1][2].
Understanding these early symptoms is no longer optional. It is the key to detecting the disease earlier—and potentially changing its trajectory.
At the core of Parkinson’s disease lies a protein called alpha-synuclein. Under normal conditions, this protein plays an essential role in neuronal communication, particularly in the regulation of dopamine release [5].
However, in Parkinson’s disease, alpha-synuclein undergoes a structural transformation. It misfolds, loses its functional configuration, and begins to accumulate into toxic aggregates known as Lewy bodies. These aggregates disrupt neuronal function, trigger inflammation, and ultimately lead to cell death [6][7].
What makes this process particularly insidious is that it unfolds silently. The misfolding and accumulation of alpha-synuclein can begin long before clinical diagnosis, during a phase where symptoms are subtle, diffuse, and often overlooked.
Among all early symptoms, chronic constipation stands out as one of the most consistently reported and scientifically supported.
This is not a simple digestive inconvenience. It reflects a dysfunction of the enteric nervous system—the network of neurons embedded in the gut, often referred to as the “second brain.”
Research shows that constipation can precede a Parkinson’s diagnosis by 10 to 20 years, making it one of the earliest detectable manifestations of the disease process [2][8].
Even more striking, misfolded alpha-synuclein has been identified in the gut at very early stages. This has led to a major shift in understanding: in a subset of patients, Parkinson’s disease may actually originate in the gastrointestinal tract before spreading to the brain [1][2].
Another early and frequently underestimated symptom is persistent fatigue. This is not the kind of fatigue that resolves with rest. It is deep, chronic, and often unexplained.
At a biological level, this fatigue reflects a disruption in mitochondrial function. Mitochondria are responsible for producing cellular energy, and their dysfunction is a well-established feature of Parkinson’s disease.
Oxidative stress and chronic inflammation impair mitochondrial efficiency, leading to reduced energy production. This affects not only the brain but the entire organism, making fatigue one of the earliest systemic manifestations of the disease [7].
Certain sleep disorders are highly predictive of future Parkinson’s disease, particularly REM sleep behavior disorder (RBD). This condition is characterized by the loss of normal muscle paralysis during dreaming, leading to physical movements during sleep.
RBD can appear years or even decades before a Parkinson’s diagnosis and is considered one of the most specific early markers of neurodegeneration.
Its presence reflects early dysfunction in brain regions that regulate sleep and motor inhibition, long before classical motor symptoms emerge [7].
A reduced or lost sense of smell, known as hyposmia, is another early symptom that is frequently ignored.
Yet, it is one of the most consistent non-motor features of Parkinson’s disease. It reflects early involvement of the olfactory bulb, one of the first brain regions affected by the spread of misfolded alpha-synuclein [8].
Because it develops gradually and does not interfere with daily functioning in an obvious way, it often goes unnoticed—despite its diagnostic value.
The gut microbiome is now recognized as a key factor in the early development of Parkinson’s disease.
Patients consistently show signs of dysbiosis, an imbalance in gut bacteria characterized by a reduction in beneficial, anti-inflammatory species and an increase in pro-inflammatory microorganisms [9].
This imbalance has profound consequences. It alters the integrity of the intestinal barrier, making it more permeable. This “leaky gut” state allows inflammatory molecules such as lipopolysaccharides to enter the bloodstream, triggering chronic low-grade inflammation [10].
This inflammatory environment promotes the misfolding and aggregation of alpha-synuclein, linking gut dysfunction directly to the core pathological mechanism of Parkinson’s disease [11].
Once initiated in the gut, the pathological process may propagate to the brain via the vagus nerve, a direct communication pathway between the digestive system and the central nervous system.
This hypothesis is supported by epidemiological studies showing that individuals who have undergone vagotomy have a reduced risk of developing Parkinson’s disease [12].
This progression—from gut dysfunction to systemic inflammation to neurodegeneration—offers a coherent explanation for the sequence of early symptoms observed in patients.
Parkinson’s disease does not begin with tremors. It begins silently, through a combination of gut dysfunction, metabolic imbalance, and early neurological changes that are often dismissed or misunderstood.
Chronic constipation, persistent fatigue, sleep disturbances, and loss of smell are not isolated symptoms. They are potential indicators of an ongoing neurodegenerative process.
Recognizing these early signs is critical. It shifts the focus from late-stage symptom management to early detection and systemic intervention—where the gut–brain connection becomes one of the most important frontiers in modern medicine.
[1] Oliver et al., The gut–brain axis in early Parkinson’s disease, 2025
https://pmc.ncbi.nlm.nih.gov/articles/PMC12092510/
[2] Menozzi et al., The Gut–Brain Axis in Parkinson Disease, 2025
https://pmc.ncbi.nlm.nih.gov/articles/PMC12275011/
[5] Burré et al., Alpha-synuclein function, Nature Reviews Neuroscience
https://www.nature.com/articles/nrn3213
[6] Brundin et al., Prion-like propagation, Nature Reviews Molecular Cell Biology
https://www.nature.com/articles/nrm3921
[7] Poewe et al., Parkinson disease, Nature Reviews Disease Primers
https://www.nature.com/articles/s41572-017-0002-2
[8] Braak et al., Staging of Parkinson’s disease
https://pubmed.ncbi.nlm.nih.gov/12498954/
[9] Jin et al., Gut microbiota dysbiosis in Parkinson’s disease, 2025
https://www.sciencedirect.com/science/article/pii/S2589004225024460
[10] Kustrimovic et al., Gut microbiota and inflammation, 2024
https://www.mdpi.com/1422-0067/25/22/12164
[11] Sampson et al., Gut microbiota regulate Parkinson’s disease, Cell
https://www.cell.com/cell/fulltext/S0092-8674(16)31590-3
[12] Svensson et al., Vagotomy and Parkinson’s disease risk
https://pubmed.ncbi.nlm.nih.gov/26878819/